NCT00136981已完成3 期
Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia.
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 800
- 试验地点
- 34
- 主要终点
- Change in intima media thickness as measures by carotid ultrasound
研究概览
简要总结
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
To look at ultrasound images taken in the carotid arteries and to look at various lipids in the blood of people with heterozygous familial hypercholesterolemia
详细描述
For additional information please call: 1-800-718-1021
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of Heterozygous Familial Hypercholesterolemia
- •At least 18 years of age
排除标准
- •Women who are pregnant or lactating, or planning to become pregnant.
- •Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid (high doses)
- •Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
- •Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluationof response, or render unlikely that the subject would complete the study
结局指标
主要结局
Change in intima media thickness as measures by carotid ultrasound
次要结局
- Changes in levels of lipids and other biomarkers.
研究者
研究点 (34)
Loading locations...
相似试验
终止
3 期
Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.Mixed HyperlipidemiaNCT00134238Pfizer755
已完成
3 期
A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart DiseaseCoronary DiseaseCoronary ArteriosclerosisHyperlipidemiaNCT00134173Pfizer1,100
已完成
3 期
Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.HyperlipidemiaNCT00137462Pfizer900
终止
3 期
A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart DiseaseCoronary DiseaseDiabetes MellitusNCT00134264Pfizer15,067
已完成
3 期
A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High TriglyceridesHyperlipoproteinemia Type IVHypertriglyceridemiaNCT00134498Pfizer160